EUCODIS Bioscience GmbH, a company providing customized enzymes to the pharmaceutical, chemical, and other industries, has received a €2m financing.
Existing investors Pontis Capital, Wiener Wachstumsfonds, IBG, and ARAX participated in the round.
EUCODIS Bioscience develops, customizes, manufactures, and markets industrial enzymes to help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.
The company will use the funds to add new enzyme families to its product portfolio and to accelerate the development of international markets.
At the same time, EUCODIS Bioscience is expanding its manufacturing capacity in pace with growing customer demand.
Commenting on the capital injection Thomas Fischer, CEO of EUCODIS Bioscience, said: “Following several product launches in 2009 and the recent expansion of our lipases family to 20 enzymes we continue to build our order book.
“Accordingly, our revenues will finance a good part of our expenses and investments this year.
“Given the wealth of business opportunities in front of us, we are extremely pleased that the cash injection will help us to broaden our product range and to ramp up our sales and marketing efforts”, he added.
The company is headquartered in Austria, with a subsidiary in Germany.